T3 Pharmaceuticals AG

https://www.t3pharma.com

T3 Pharma was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The Company is focusing on immuno-oncology (bacteria-based) therapies for the treatment of solid tumors. Cancer immunotherapy is seen as a turning point in the fight against cancer. Unlike traditional therapies that attack the tumor directly, the goal of immunotherapies is to stimulate the immune system to selectively recognize and attack tumor cells. T3 is among the first companies supported by BaseLaunch. It was awarded «Science Startup of the year 2018» at Falling Walls Venture, won the Venture.ch business plan competition in 2016 and recently the W.A. de Vigier Award. *

	Start	2015-05-01 established (s-offc
	Predecessor	University of Basel
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	bacterial treatment (bacteria as »drug«)
	Person	Ittig, Simon Josef (T3 Pharmaceuticals 201909 CEO + Co-Founder)
	Person 2	Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)

	Region	Basel BS
	Country	Switzerland
	Street	50/70 Klingelbergstr. c/o Biozentrum, Universität Basel
	City	4056 Basel
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: T3 Pharmaceuticals AG. (9/26/19). "Press Release: Closing of Financing Round and Strengthening of Development Team Paves the Way for T3 Pharma to Enter the Clinic".

		Record changed: 2020-10-22